LFVN Lifevantage

EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against LifeVantage Corporation – LFVN

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of LifeVantage Corporation securities (NASDAQ:LFVN) from November 4, 2015 through September 13, 2016, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for LifeVantage investors under the federal securities laws.

To join the LifeVantage class action, go to the firm’s website at http://www.rosenlegal.com/cases-952.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll free at 866-767-3653 or email [email protected] or [email protected] for more information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, throughout the Class Period defendants issued false and misleading statements to investors and/or failed to disclose that: (1) LifeVantage lacked effective internal financial controls; (2) LifeVantage had improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and (3) as a result, defendants’ statements about LifeVantage’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 14, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-952.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

Kevin Chan, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 34th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

EN
16/09/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lifevantage

 PRESS RELEASE

LifeVantage To Open Iceland Market

LifeVantage To Open Iceland Market Launch delivers innovative business opportunity and top wellness products to Iceland, marking a bold step in European expansion SALT LAKE CITY, July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced its upcoming launch into Iceland expected in September. This marks the company’s continued partnership with its field leadership on international expansion and reinforces its commitment to delivering science-backed wellness so...

 PRESS RELEASE

LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1...

LifeVantage Announces Expanded Human Clinical Study for MindBody GLP-1 System™; Findings Increase Average in Natural GLP-1 Production to Over 200%‡‡ Expanded U.S.-clinical research study shows strong results including increased fat loss, improved cravings control, and healthier body composition*‡ SALT LAKE CITY, July 22, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced new results from its second human clinical study on the , revealing even more compelling ou...

 PRESS RELEASE

LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campai...

LifeVantage Hosts Activate 2025, Unveils New Quarterly Business Campaign and Incentive to Drive Global Growth SALT LAKE CITY, July 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, held its global Activate 2025 virtual event on Saturday, July 12. The event, supported by Consultant-hosted watch parties and local in-person gatherings, provided a dynamic platform to inspire Consultant business engagement and growth. Activate 2025 also celebrated innovation, reinforcing LifeVan...

 PRESS RELEASE

LifeVantage Declares Quarterly Dividend

LifeVantage Declares Quarterly Dividend SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today announced that the Company’s Board of Directors has approved a quarterly cash dividend of $0.045 per share of common stock, which will be paid June 13, 2025 to all stockholders of record at the close of business on May 30, 2025. This represents an increase in the dividend amount by 12.5% over the previous quarter. About LifeVantage Corpo...

 PRESS RELEASE

LifeVantage Announces Financial Results for the Third Quarter of Fisca...

LifeVantage Announces Financial Results for the Third Quarter of Fiscal 2025 SALT LAKE CITY, May 06, 2025 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its third fiscal quarter ended March 31, 2025. Third Quarter Fiscal 2025 Summary*: Revenue was $58.4 million, an increase of 21.1% from the prior year period. Excluding the negative impact of foreign currency fluctuations, third quarter revenue increased approximat...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch